CN1649893A - 作为血管肽酶抑制剂的带有n－末端2－酰硫基的二肽衍生物 - Google Patents

作为血管肽酶抑制剂的带有n－末端2－酰硫基的二肽衍生物 Download PDF

Info

Publication number
CN1649893A
CN1649893A CNA028118499A CN02811849A CN1649893A CN 1649893 A CN1649893 A CN 1649893A CN A028118499 A CNA028118499 A CN A028118499A CN 02811849 A CN02811849 A CN 02811849A CN 1649893 A CN1649893 A CN 1649893A
Authority
CN
China
Prior art keywords
expression
alkyl group
low alkyl
hydrogen
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028118499A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·芬克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1649893A publication Critical patent/CN1649893A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA028118499A 2001-05-15 2002-05-14 作为血管肽酶抑制剂的带有n－末端2－酰硫基的二肽衍生物 Pending CN1649893A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29108801P 2001-05-15 2001-05-15
US60/291,088 2001-05-15
US33957501P 2001-12-11 2001-12-11
US60/339,575 2001-12-11

Publications (1)

Publication Number Publication Date
CN1649893A true CN1649893A (zh) 2005-08-03

Family

ID=26966569

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028118499A Pending CN1649893A (zh) 2001-05-15 2002-05-14 作为血管肽酶抑制剂的带有n－末端2－酰硫基的二肽衍生物

Country Status (23)

Country Link
US (3) US6777443B2 (https=)
EP (2) EP1392720A2 (https=)
JP (1) JP4390458B2 (https=)
KR (1) KR100908152B1 (https=)
CN (1) CN1649893A (https=)
AR (1) AR035890A1 (https=)
AU (1) AU2002314067B2 (https=)
BR (1) BR0209652A (https=)
CA (1) CA2449292A1 (https=)
CO (1) CO5540347A2 (https=)
CZ (1) CZ20033077A3 (https=)
HU (1) HUP0304084A3 (https=)
IL (1) IL158772A0 (https=)
MX (1) MXPA03010403A (https=)
MY (1) MY127495A (https=)
NO (1) NO20035084L (https=)
NZ (1) NZ529438A (https=)
PE (1) PE20030042A1 (https=)
PL (1) PL366786A1 (https=)
RU (1) RU2298559C2 (https=)
SK (1) SK14032003A3 (https=)
TW (1) TWI295996B (https=)
WO (1) WO2002092622A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113956183A (zh) * 2021-10-28 2022-01-21 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法
WO2024230583A1 (zh) * 2023-05-05 2024-11-14 上海济煜医药科技有限公司 一种短肽类化合物及其制备方法和医药应用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
HUP0401014A2 (hu) * 2001-07-06 2004-08-30 Teva Pharmaceutical Industries Ltd. Eljárás 7-amino-szin-3,5-dihidroxi-heptánsavszármazékok előállítására, 6-ciano-szin-3,5-dihidroxi-hexánsav származékokon keresztül
CA2456281A1 (en) * 2001-09-21 2003-04-03 Novartis Ag Pyrane derivatives as both ace- and nep- inhibitors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
DK1467728T3 (da) * 2002-01-17 2007-12-27 Novartis Ag Farmaceutiske sammensætninger indeholdende valsartan og NEP-inhibitorer
WO2003105837A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
RU2410118C2 (ru) * 2004-12-15 2011-01-27 Зольвай Фармасьютиклз Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
JP2008533109A (ja) * 2005-03-14 2008-08-21 オリオン コーポレーション 利尿を促進するための複合治療
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof
US7400236B2 (en) 2005-10-21 2008-07-15 Gm Global Technology Operations, Inc. Vehicular lane monitoring system utilizing front and rear cameras
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
JP2011506459A (ja) 2007-12-11 2011-03-03 セラヴァンス， インコーポレーテッド 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
EP2297113A1 (en) 2008-04-29 2011-03-23 Theravance, Inc. Dual-acting antihypertensive agents
WO2010011821A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
EP2451782B1 (en) 2009-07-07 2016-11-09 Theravance Biopharma R&D IP, LLC Dual-acting pyrazole antihypertensive agents
JP2012533626A (ja) 2009-07-22 2012-12-27 セラヴァンス， インコーポレーテッド 二重作用オキサゾール降圧剤
WO2011090929A1 (en) 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
EA201391421A1 (ru) * 2011-03-31 2014-02-28 Апотекс Текнолоджиз Инк. Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана
US9212206B1 (en) * 2014-11-24 2015-12-15 William H Simmons 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US11396497B2 (en) 2018-05-04 2022-07-26 New Mexico Tech University Research Park Corporation Proteasome inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432307A1 (de) * 1984-09-03 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Aminosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
AU6733190A (en) * 1989-11-27 1991-06-26 Santen Pharmaceutical Co. Ltd. Amino acid derivative
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
EP0580550B1 (en) 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
US5432186A (en) * 1993-11-16 1995-07-11 Ciba-Geigy Corporation Cyclic amino acid derivatives
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
EP0820464A2 (en) * 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
DE69632821T2 (de) * 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka In wasser hochlöslicher metalloproteinase-inhibitor
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use
EP0830368A1 (en) * 1995-06-07 1998-03-25 Genta Incorporated Novel carbamate-based cationic lipids
US6245809B1 (en) * 1996-12-09 2001-06-12 Cor Therapeutics Inc. Integrin antagonists
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19745151A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue Verbindungen zur Behandlung von Krankheiten, die mit der biologischen Wirkung von Endothelin assoziiert sind
FR2770844A1 (fr) 1997-11-10 1999-05-14 Inst Nat Sante Rech Med Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant
AU1457299A (en) * 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
EP1080104B1 (en) 1998-04-23 2005-02-09 Novartis AG Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
JP4350306B2 (ja) 1998-04-23 2009-10-21 ノバルティス アクチエンゲゼルシャフト エンドセリン変換酵素のチオール型阻害剤
ES2188277T3 (es) 1998-12-31 2003-06-16 Aventis Pharma Inc Inhibidores selectivos de mmp-12.
FR2788526B1 (fr) 1999-01-20 2002-07-05 Inst Nat Sante Rech Med Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
GB9917909D0 (en) * 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
CN1235875C (zh) * 1999-08-27 2006-01-11 西托维亚公司 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
US6803383B2 (en) * 2000-03-27 2004-10-12 The Scripps Research Institute Inhibition of angiogenesis and tumor growth
JP2003533440A (ja) 2000-04-03 2003-11-11 ブリストル−マイヤーズ スクイブ カンパニー 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
IL152081A0 (en) 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
US20020013307A1 (en) 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113956183A (zh) * 2021-10-28 2022-01-21 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法
WO2024230583A1 (zh) * 2023-05-05 2024-11-14 上海济煜医药科技有限公司 一种短肽类化合物及其制备方法和医药应用

Also Published As

Publication number Publication date
WO2002092622A8 (en) 2004-01-22
CO5540347A2 (es) 2005-07-29
AR035890A1 (es) 2004-07-21
NZ529438A (en) 2005-07-29
WO2002092622A2 (en) 2002-11-21
JP4390458B2 (ja) 2009-12-24
EP2239268A1 (en) 2010-10-13
IL158772A0 (en) 2004-05-12
TWI295996B (en) 2008-04-21
MY127495A (en) 2006-12-29
CZ20033077A3 (cs) 2004-02-18
JP2005504011A (ja) 2005-02-10
PE20030042A1 (es) 2003-02-28
KR20030096401A (ko) 2003-12-24
US20020183260A1 (en) 2002-12-05
HUP0304084A3 (en) 2010-10-28
CA2449292A1 (en) 2002-11-21
BR0209652A (pt) 2004-07-13
PL366786A1 (en) 2005-02-07
EP1392720A2 (en) 2004-03-03
US20060058242A1 (en) 2006-03-16
SK14032003A3 (sk) 2004-06-08
RU2003134153A (ru) 2005-06-10
MXPA03010403A (es) 2004-03-09
RU2298559C2 (ru) 2007-05-10
AU2002314067B2 (en) 2006-03-16
HUP0304084A2 (hu) 2004-12-28
US6992105B2 (en) 2006-01-31
NO20035084D0 (no) 2003-11-14
US6777443B2 (en) 2004-08-17
WO2002092622A3 (en) 2003-04-10
KR100908152B1 (ko) 2009-07-16
NO20035084L (no) 2004-01-15
US20040235754A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
CN1649893A (zh) 作为血管肽酶抑制剂的带有n－末端2－酰硫基的二肽衍生物
CN1192035C (zh) 白介素－1β转化酶抑制剂
CN1133648C (zh) 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物
CN1146575C (zh) 用于治疗与凝血酶有关的疾病的肽基杂环化合物
CN1195778C (zh) 细胞粘附抑制剂
CN1265675A (zh) 抑制由vla－4介导的白细胞粘着的苄基化合物
CN1265670A (zh) 抑制vla－4介导的白细胞粘附的二肽和相关的化合物
CN1515550A (zh) 抗血栓形成剂
CN1418193A (zh) 含有杂环侧链的金属蛋白酶抑制剂
AU2002314067A1 (en) Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
CN1237978A (zh) N－(芳基/杂芳基)氨基酸衍生物、包括这些衍生物的药用组合物以及用这些化合物抑制β－淀粉样肽释放和或其合成的方法
CN1304415C (zh) 作为ace和nep抑制剂的吡喃衍生物
CN1228783A (zh) 新的凝血酶抑制剂
CN1058019C (zh) 环状氨基酸衍生物
CN1291993A (zh) 用作半胱氨酸活性依赖性酶抑制剂的噻二唑化合物
HK1046289A1 (zh) 凝血酶抑制剂的前体药物
CN1425004A (zh) 含杂环侧链的n－取代的金属蛋白酶抑制剂
CN1195773C (zh) 可以抑制由vla－4介导的白细胞粘着的焦谷氨酸衍生物及相关化合物
CN1135717A (zh) 抗血栓形成的氮杂环烷基链烷酰肽和假肽
CN1809345A (zh) 依那普利－硝基衍生物和相关化合物作为ace抑制剂用于治疗心血管疾病
CN1185250C (zh) 可以抑制由vla－4介导的白细胞粘着的化合物
HK1045516A1 (zh) 凝血酶抑制剂的前药
HK1071893A (en) Pyrane derivatives as both ace-and nep-inhibitors
CN1976945A (zh) 异肽间隙连接调节剂
HK1022702A (en) Thrombin inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050803